Dr. Reddy’s Hopes U.S. FDA Visit Will Clear Mexico Production Facility
This article was originally published in PharmAsia News
India-based Dr. Reddy’s Laboratories expects a visit by U.S. FDA inspectors at its production facility in Mexico by the end of March, a visit it hopes will lead to release of its products into the U.S.
You may also be interested in...
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.
The two companies announced more details about their COVID-19 vaccine development plan, including a $185m upfront payment and $113m equity investment from Pfizer.